Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 01 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Glucocorticoids
Indications Takayasu syndrome
Focus Registrational; Therapeutic Use
Sponsors Janssen Pharmaceutical KK

Most Recent Events

27 Jun 2023 The project has been decided to be early termination on 10Feb2023 due to company prioritization.
11 Apr 2023 Planned End Date changed from 11 Jun 2025 to 8 Jun 2023.
11 Apr 2023 Planned primary completion date changed from 30 Jun 2023 to 8 Jun 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com